Delcath Systems, Inc. on Preliminary List of Additions to Russell Microcap® Index

NEW YORK, June 13, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it expects to be added to the Russell Microcap® Index according to a preliminary list of additions posted on June 10, 2011 at www.russell.com/indexes, and will remain a component of the Russell 3000® and Russell 2000® Indexes, when Russell Investments reconstitutes its family of U.S. indexes on June 24, 2011 after the close of the U.S. markets.

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market and is comprised of the smallest 1,000 companies in the Russell 3000 Index, plus the next smallest 1,000 companies. Inclusion in the Russell Microcap Index will remain in place for the ensuing 12-month period. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. According to Russell Investments, $3.9 trillion in institutional assets currently are benchmarked to its indexes. The indexes are reconstituted annually.

About Delcath Systems

Delcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath’s proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company’s initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multiarm Phase II trial to treat other liver cancers. The Company received CE Mark approval for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company’s website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forwardlooking statements made by the Company or on its behalf. This news release contains forwardlooking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company’s NDA by the FDA, approval of the Company’s NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities, and uncertainties relating to the impact, if any, of being added to the Russell Microcap Index. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forwardlooking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forwardlooking statements to reflect events or circumstances after the date they are made

SOURCE Delcath Systems, Inc.